These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 15995024)

  • 1. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.
    Korinthenberg R; Schessl J; Kirschner J; Mönting JS
    Pediatrics; 2005 Jul; 116(1):8-14. PubMed ID: 15995024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.
    Kuitwaard K; de Gelder J; Tio-Gillen AP; Hop WC; van Gelder T; van Toorenenbergen AW; van Doorn PA; Jacobs BC
    Ann Neurol; 2009 Nov; 66(5):597-603. PubMed ID: 19938102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study.
    Korinthenberg R; Schessl J; Kirschner J
    Neuropediatrics; 2007 Feb; 38(1):10-7. PubMed ID: 17607598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.
    DiMario FJ
    Pediatrics; 2005 Jul; 116(1):226-8. PubMed ID: 15995056
    [No Abstract]   [Full Text] [Related]  

  • 5. Motor recovery after Guillain-Barré syndrome in childhood.
    Ortiz-Corredor F; Peña-Preciado M; Díaz-Ruíz J
    Disabil Rehabil; 2007 Jun 15-30; 29(11-12):883-9. PubMed ID: 17577723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of immunoglobulin in severe childhood Guillain-Barré syndrome.
    Ortiz-Corredor F; Peña-Preciado M
    Acta Neurol Scand; 2007 Apr; 115(4):289-93. PubMed ID: 17376129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Guillain-Barré syndrome: epidemiological, clinical and therapeutic insight].
    Raphaël JC; Sharshar T
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S35-40. PubMed ID: 10896987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
    Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Guillain-Barre syndrome and IVIg: does early initiation of treatment influence the mean hospital stay?].
    Coll-Cantí J; Alvarez-Ramo R; Dorado L; Guerrero C; Serichol M; Dávalos A; Martínez EM
    Neurologia; 2009 May; 24(4):217-9. PubMed ID: 19603290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Present treatment of Guillain-Barre syndrome].
    Raphaël JC
    Bull Acad Natl Med; 2004; 188(1):87-94; discussion 94-5. PubMed ID: 15368928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae.
    Mitchell WG; Davalos-Gonzalez Y; Brumm VL; Aller SK; Burger E; Turkel SB; Borchert MS; Hollar S; Padilla S
    Pediatrics; 2002 Jan; 109(1):86-98. PubMed ID: 11773546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome.
    Ann Neurol; 1997 Mar; 41(3):298-306. PubMed ID: 9066350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Guillain-Barré syndrome in childhood].
    Kollár K; Liptai Z; Rosdy B; Móser J
    Ideggyogy Sz; 2009 Nov; 62(11-12):399-404. PubMed ID: 20025130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain-Barre syndrome.
    Reuben S; Sumi MG; Mathai A; Nair MD; Radhakrishnan VV
    Neurol India; 2003 Dec; 51(4):487-9. PubMed ID: 14742928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of Guillain-Barré syndrome with high-dose intravenous immunoglobulins--a comparison with plasma exchange].
    Kamei T; Nakagawa H; Uchiyama F; Fukuyama J
    Rinsho Shinkeigaku; 1993 Jun; 33(6):660-2. PubMed ID: 8403689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
    J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
    van Doorn PA
    Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Factors affecting prognosis in childhood Guillain Barré syndrome].
    Ortiz Corredor F
    Rev Neurol; 2004 Mar 16-31; 38(6):518-23. PubMed ID: 15054714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.